Research Article
No access
Published Online: 23 September 2005

Variation in Pediatric Aerosol Delivery: Importance of Facemask

Publication: Journal of Aerosol Medicine
Volume 18, Issue Number 3

Abstract

We have quantified in vitro the influence of the facemask on the amount of drug delivered (e.g., inhaled mass) by jet nebulizer and pressurized metered dose inhaler (pMDI) valved holding chamber (VHC) combinations (non-detergent-coated and detergent-coated). Pediatric breathing patterns were used with a breathing simulator, which was connected to a face onto which each device was positioned. An inhaled mass filter interposed between the simulator and the face captured the aerosolized drug. Budesonide inhalation suspension (0.25 mg) was used with the jet nebulizers and fluticasone propionate (220 µg) pMDI with the VHCs. Maximal drug delivery was measured using constant flow through each device. Breathing pattern effects were assessed for sealed devices (no leaks) and with facemasks (possible leaks at the facemask). Inhaled mass from both nebulizers and pMDI VHCs was affected by breathing pattern, but compared to nebulizers the pMDI VHCs were significantly more variable and sensitive to several factors. The influence of VHC conditioning combined with effects of breathing pattern resulted in the inhaled mass ranging from 0.7 ± 0.5 to 53.3 ± 6.2%. Nebulizers were less variable (9.6 ± 0.7 to 24.3 ± 3.1%). Detergent coating of VHC markedly increased the inhaled mass and reproducibility of drug delivery (27.2 ± 1.4 to 53.3 ± 6.2%) for pMDI VHC combinations, but these effects were lost in the presence of facemasks. Using pediatric patterns of breathing, nebulizer/facemask combinations delivered 4.1 ± 0.8 to 19.3 ± 2.3% of the label dose while pMDI and detergent-coated VHC delivered 4.0 ± 1.6 to 28.6 ± 2.5%. Facemask seal is a key factor in drug delivery. Leaks around the facemask reduce drug delivery and for pMDI VHCs can negate effects of detergent coating.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Journal of Aerosol Medicine
Journal of Aerosol Medicine
Volume 18Issue Number 3Fall 2005
Pages: 354 - 363
PubMed: 16181009

History

Published online: 23 September 2005
Published in print: Fall 2005

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Gerald C. Smaldone
Pulmonary/Critical Care Medicine, SUNY at Stony Brook, Stony Brook, New York.
Elna Berg
AstraZeneca R&D Lund, Lund, Sweden.
Kurt Nikander
Respironics, Inc., Cedar Grove, New Jersey.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top